To the full analysis
Shenzhen Salubris Pharmaceuticals stock: growth
002294.SZShenzhen Salubris Pharmaceuticals reported $645.86M in revenue for fiscal 2025, up 7.3% on the prior year.
Revenue (Annual rate)
17.4%
per year from 2006 to 2025, per share 14.2%
Earnings (Annual rate)
16.8%
per year from 2006 to 2025, per share 13.5%
Free cash flow (Annual rate)
24.3%
per year from 2006 to 2025, per share 20.9%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 9.5% | 2.2% | 17.4% |
| Revenue per share | 7.7% | 1.5% | 14.2% |
| Earnings | 60.7% | −6.4% | 16.8% |
| Earnings per share | 57.8% | −7.1% | 13.5% |
| Free cash flow | −27.8% | −16.0% | 24.3% |
| Free cash flow per share | −28.9% | −16.5% | 20.9% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $30.46M | $5.13M | $344.82K |
| 2007 | $52.4M | $10.97M | $5.86M |
| 2008 | $79.06M | $17.54M | $2.46M |
| 2009 | $127.41M | $32.35M | −$209.17K |
| 2010 | $194.62M | $53.28M | −$5.52M |
| 2011 | $221.18M | $60.77M | $2.96M |
| 2012 | $274.27M | $95.25M | $35.16M |
| 2013 | $349.04M | $124.53M | $36.19M |
| 2014 | $432.29M | $156.31M | $117.21M |
| 2015 | $521.53M | $189.84M | $123.04M |
| 2016 | $574.89M | $209.41M | $178.42M |
| 2017 | $622.92M | $217.73M | $168.87M |
| 2018 | $697.61M | $218.68M | $151.13M |
| 2019 | $670.41M | $107.25M | $157.38M |
| 2020 | $410.69M | $9.13M | $109.75M |
| 2021 | $458.65M | $80.04M | $105.35M |
| 2022 | $522.18M | $95.54M | $55.76M |
| 2023 | $504.68M | $86.99M | $25.26M |
| 2024 | $601.69M | $90.21M | $84.2M |
| 2025 | $645.86M | $97.7M | $21.58M |
Data status and sources
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 31 Jul 2024)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.